Cullinan Therapeutics, Inc. announced that it will present results from the REZILIENT1 study of zipalertinib, a treatment for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion ...
Lexicon Pharmaceuticals announced that it will present data on diabetic peripheral neuropathic pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results